Browsing by author "Chapman, Jeremy R"
Sort by:
Title A-Z
-
Belatacept for kidney transplant recipients
Masson, Philip; Henderson, Lorna; Chapman, Jeremy R; Craig, Jonathan C; Webster, Angela CPublished 2014-11-24Background Most people who receive a kidney transplant die from either cardiovascular disease or cancer before their transplant fails. The most common reason for someone with a kidney transplant to lose the function of ...Open AccessArticle -
Interleukin 2 Receptor Antagonists for Kidney Transplant Recipients
Webster, Angela C; Ruster, Lorenn P; McGee, Richard; Matheson, Sandra L; Higgins, Gail Y; Willis, Narelle S; Chapman, Jeremy R; Craig, Jonathan CPublished 2010-01-20Background Interleukin 2 receptor antagonists (IL2Ra) are used as induction therapy for prophylaxis against acute rejection in kidney transplant recipients. Use of IL2Ra has increased steadily since their introduction, ...Open AccessArticle -
Interleukin 2 Receptor Antagonists for Kidney Transplant Recipients
Webster, Angela C; Playford, Elliott Geoffrey; Higgins, Gail Y; Chapman, Jeremy R; Craig, Jonathan CPublished 2004-01-26Background: Interleukin 2 receptor antagonists (IL2Ra) are used as induction therapy for prophylaxis against acute rejection in kidney transplant recipients. Use of IL2Ra has increased steadily, with 38% of new kidney ...Open AccessArticle -
Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients
Webster, Angela C; Wu, Sunny; Tallapragada, Krishna; Park, Min Young; Chapman, Jeremy R; Carr, Sue JPublished 2017-07-20Background Registry data shows that the incidence of acute rejection has been steadily falling. Approximately 10% to 35% of kidney recipients will undergo treatment for at least one episode of acute rejection within the ...Open AccessArticle -
Polyclonal and Monoclonal Antibodies for Treating Acute Rejection Episodes in Kidney Transplant Recipients
Webster, Angela C; Pankhurst, Tanya; Rinaldi, Fiona; Chapman, Jeremy R; Craig, Jonathan CPublished 2006-04-19Background: Registry data shows that between 15-35% kidney recipients will undergo treatment for at least one episode of acute rejection within the first post transplant year. Treatment options include pulsed steroid ...Open AccessArticle -
Research priorities in chronic kidney disease for Australia: Report of a conference
Tong, Allison; Crowe, Sally; Chando, Shingisai; Cass, Alan; Chadban, Steve J; Chapman, Jeremy R; Gallagher, Martin; Hawley, Carmel M; Hill, Sophie; Howard, Kirsten; Johnson, David W; Kerr, Peter G; McKenzie, Anne; Parker, David; Perkovic, Vlado; Polkinghorne, Kevan R; Pollock, Carol; Strippoli, Giovanni FM; Tugwell, Peter; Walker, Rowan G; Webster, Angela C; Wong, Germaine; Craig, Jonathan CPublished 2015-05-03Research aims to improve health outcomes for patients. However, the setting of research priorities is usually performed by clinicians, academics, and funders, with little involvement of patients or caregivers and using ...Open AccessArticle -
Tacrolimus Versus Cyclosporin as Primary Immunosuppression for Kidney Transplant Recipients
Webster, Angela C; Taylor, Rod RS; Chapman, Jeremy R; Craig, Jonathan CPublished 2005-10-19Background: Kidney transplantation is the treatment of choice for most patients with end-stage renal disease (ESRD). Standard protocols in use typically involve three drug groups each directed to a site in the T-cell ...Open AccessArticle -
Target of Rapamycin Inhibitors (TOR-I; Sirolimus and Everolimus) for Primary Immunosuppression in Kidney Transplant Recipients
Webster, Angela C; Lee, Vincent WS; Chapman, Jeremy R; Craig, Jonathan CPublished 2006-04-19Background: Target of rapamycin inhibitors (TOR-I) (sirolimus, everolimus) are immunosuppressive agents with a novel mode of action but an uncertain clinical role. Objectives: To investigate the benefits and harms of ...Open AccessArticle -
Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients
Hahn, Deirdre; Hodson, Elisabeth M; Hamiwka, Lorraine A; Lee, Vincent WS; Chapman, Jeremy R; Craig, Jonathan C; Webster, Angela CPublished 2019-12-16Background Kidney transplantation is the therapy of choice for many patients with end‐stage kidney disease (ESKD) with an improvement in survival rates and satisfactory short term graft survival. However, there has been ...Open AccessArticle -
Test performance of faecal occult blood testing for the detection of bowel cancer in people with chronic kidney disease (DETECT) protocol
Wong, Germaine; Howard, Kirsten; Chapman, Jeremy R; Tong, Allison; Bourke, Michael J; Hayen, Andrew; Macaskill, Petra; Hope, Richard L; Williams, Narelle; Kieu, Anh; Allen, Richard; Chadban, Steven; Pollock, Carol; Webster, Angela C; Roger, Simon D; Craig, Jonathan CPublished 2011-06-29Background: Cancer is a major cause of mortality and morbidity in patients with chronic kidney disease (CKD). In patients without kidney disease, screening is a major strategy for reducing the risk of cancer and improving ...Open AccessArticle
Sort by:
Title A-Z